Dear Editor, Red blood cell (RBC) genotyping is recommended to limit alloimmunization in patients with sickle cell disease or thalassemia [1] . RBC genotyping can resolve the serologic weak D phenotype and inconclusive RhD typing in obstetrics and identify the RBC phenotype in patients with autoantibodies or a positive direct antiglobulin test (DAT) [2] . DNA-based RBC typing has better accuracy and provides more information on RBC antigens than typical phenotyping [1] .
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We report a challenging case of a pregnant patient in whom a lack of compatible RBCs, based on RBC genotyping, suggested the presence of anti-Di b and anti-E specificities. To our knowledge, extended RBC genotyping was used to obtain compatible RBC units for the first time in Korea.
A 36-year-old Korean woman (gravida 2, para 0) came to Pusan National University Hospital for prenatal care. She had a history of blood transfusion at the age of 12 years. Her blood type was B and RhD positive, and she tested positive for irregular antibodies at 30 weeks of gestation. All panels, except for auto-control, were reactive in RBC antibody screening. However, we could not determine the types of the unexpected antibodies; moreover, detection of compatible RBCs was difficult due to the presence of unexpected antibodies. We obtained one unit of compatible packed RBCs (matched for Rh, Kell, Duffy, and Kidd) for practicable 350-unit cross matching and one unit of whole blood from autologous blood donation. The study protocol was approved by the institutional review board of Pusan National University Hospital, and written informed consent was obtained from the patient. Extended genotyping of 37 RBC antigens with the ID CORE XT kit (Progenika Biopharma-Grifols, Bizkaia, Spain) that is based on Luminex xMAP technology predicted the rare blood type Di(a+b−) ( Table 1) . We hypothesized that the lack of a com- [3] . In a report from Korea, the prevalence of the predictive phenotype Di(a+b−) was 0.7% (3/419) in healthy Korean donors [4] . Anti-Di b was observ ed in four cases of hemolytic disease in newborns [5] [6] [7] [8] and two adult cases in which no matched blood products could be found for orthopedic surgery [9] . In another report, Anti-Di b were detected through a reaction with blood cells for the identification of an unexpected antibody with the Di(a+b−) phenotype; the genotype of the Diego blood type could not be identified [7] . In another case, Di b was detected through genotyping of the Diego blood type by direct sequencing of SLC4A1, which encodes the erythroid band 3 protein anion exchanger 1 (AE1) glycoprotein. A mutation resulting in a single amino acid change in this protein resulted in the production of the Diego antigen [3, 9] . Hospitals typically perform time-consuming serologic tests on site to locate antigen-negative RBC units [10] . Antibodies against HFA may be difficult to identify due to a lack of negative panel cells; thus, identifying compatible antigen-negative blood can be challenging. In this case, reactions with all panel cells were positive (except for the auto-control). As it is difficult to identify antibodies in the hospital, samples are typically sent to a reference blood bank or laboratory for antibody identification through additional tests; however, this process is time-consuming. In this case, we could predict anti-Di b antibodies through extended RBC genotyping because we suspected antibodies against HFAs. RBC genotyping can be performed immediately at the hospital. In conclusion, in cases in which antibody identification and detection of compatible RBCs are difficult, antibodies against HFAs can be suspected. Extended RBC genotyping is a useful tool to identify specific anti-HFA antibodies and identify compatible RBCs for patients with these antibodies in transfusion medicine laboratories at hospitals. 
